Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | PDE5A | O76074 | 4/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34464880 | 0.90 | SMO (0.34) | JAK2JAK1JAK3SMOPDE5A | |
| SCHEMBL34464827 | 0.88 | JAK2 (0.46) | HDAC3HDAC8JAK2JAK1JAK3 | |
| SCHEMBL34464816 | 0.83 | HDAC3 (0.41) | HDAC3HDAC8JAK2JAK1JAK3 | |
| SCHEMBL34464791 | 0.81 | JAK2 (0.35) | JAK2JAK1JAK3SMOHDAC1 | |
| SCHEMBL34464825 | 0.72 | PIK3CA (0.39) | JAK2JAK1JAK3HDAC1 | |
| SCHEMBL34464803 | 0.69 | PIK3CA (0.52) | HDAC3HDAC8JAK2JAK1JAK3 | |
| SCHEMBL34464785 | 0.68 | HDAC1 (0.52) | HDAC3HDAC8JAK2JAK1JAK3 | |
| SCHEMBL34464870 | 0.66 | CYP3A4 (0.45) | JAK2ALDH1A1 | |
| SCHEMBL34464755 | 0.64 | TBK1 (0.36) | HDAC3HDAC8JAK2JAK1JAK3 | |
| SCHEMBL26683442 | 0.64 | HDAC3 (0.60) | HDAC3HDAC8HDAC2HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | BAERENKRAFT THERAPEUTICS LLC (US) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | HDAC6, HDAC3, HDAC1 | HDAC3 2/4885HDAC8 6/4885JAK2 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.